Halftime Report cover image

Record High Strategies 10/24/25

Halftime Report

00:00

Merck and Healthcare Dividend Opportunities

Kevin discusses buying Merck for acquisition upside, dividend yield, and recovery as Keytruda patent concerns ease.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app